{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:15:09Z","timestamp":1760267709748,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Fondazione Buzzi"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.lungcan.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T11:10:31Z","timestamp":1581505831000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma"],"prefix":"10.1016","volume":"142","author":[{"given":"Paolo Andrea","family":"Zucali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"De Vincenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Cordua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.02.005_bib0005","doi-asserted-by":"crossref","unstructured":"J.M. Mazurek, G. Syamlal, MBBS et al., \u2018Malignant Mesothelioma Mortality \u2014 United States, 1999\u20132015\u2019, Centers for disease Control and Prevention. https:\/\/www.cdc.gov\/mmwr\/volumes\/66\/wr\/mm6608a3.htm. Last accessed: 21th August 2019.","DOI":"10.15585\/mmwr.mm6608a3"},{"issue":"July 14","key":"10.1016\/j.lungcan.2020.02.005_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cis- platin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"March 9","key":"10.1016\/j.lungcan.2020.02.005_bib0015","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"Febuary 3","key":"10.1016\/j.lungcan.2020.02.005_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11864-019-0616-7","article-title":"Malignant pleural mesothelioma: is tailoring the second-line therapy really \"raising the bar?\"","volume":"20","author":"Di Noia","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"Febuary 1","key":"10.1016\/j.lungcan.2020.02.005_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"March 3","key":"10.1016\/j.lungcan.2020.02.005_bib0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"issue":"January 2suppl","key":"10.1016\/j.lungcan.2020.02.005_bib0035","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.21037\/jtd.2017.10.131","article-title":"Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma","volume":"10","author":"Zucali","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"Febuary 2","key":"10.1016\/j.lungcan.2020.02.005_bib0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"Juyl 7","key":"10.1016\/j.lungcan.2020.02.005_bib0045","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/crj.12938","article-title":"Current treatments and trials in malignant pleural mesothelioma","volume":"12","author":"Bibby","year":"2018","journal-title":"Clin. Respir. J."},{"issue":"January 1","key":"10.1016\/j.lungcan.2020.02.005_bib0050","first-page":"149","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"August 2","key":"10.1016\/j.lungcan.2020.02.005_bib0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1309\/XL6K-8E62-9FLD-V8Q8","article-title":"Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies","volume":"116","author":"Roberts","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"issue":"October 17suppl","key":"10.1016\/j.lungcan.2020.02.005_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0093-7754(01)90100-9","article-title":"Platelet-derived growth factor receptors: a therapeutic target in solid tumors","volume":"28","author":"George","year":"2001","journal-title":"Semin. Oncol."},{"issue":"January 1","key":"10.1016\/j.lungcan.2020.02.005_bib0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance","volume":"25","author":"Taylor","year":"2006","journal-title":"Oncogene"},{"issue":"October 1","key":"10.1016\/j.lungcan.2020.02.005_bib0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.04.010","article-title":"Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial","volume":"50","author":"Mathy","year":"2005","journal-title":"Lung Cancer"},{"issue":"August 8","key":"10.1016\/j.lungcan.2020.02.005_bib0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/thx.2006.069872","article-title":"Preliminary data suggestive of a novel translational approach to mesothelioma therapy: imatinib mesylate with gemcitabine or pemetrexed","volume":"62","author":"Bertino","year":"2007","journal-title":"Thorax"},{"issue":"January 2","key":"10.1016\/j.lungcan.2020.02.005_bib0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-07-1388","article-title":"Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts","volume":"14","author":"Bertino","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"May 7","key":"10.1016\/j.lungcan.2020.02.005_bib0085","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejca.2005.12.010","article-title":"Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours","volume":"42","author":"George","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"October 19","key":"10.1016\/j.lungcan.2020.02.005_bib0090","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1158\/1078-0432.CCR-07-0883","article-title":"Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors","volume":"13","author":"Ali","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"Febuary 2","key":"10.1016\/j.lungcan.2020.02.005_bib0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"year":"2006","series-title":"Common Toxicity Criteria Manual, Version 3.0, August 9","author":"National Cancer Institute","key":"10.1016\/j.lungcan.2020.02.005_bib0100"},{"issue":"November 33","key":"10.1016\/j.lungcan.2020.02.005_bib0105","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"June 3","key":"10.1016\/j.lungcan.2020.02.005_bib0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"issue":"April 7","key":"10.1016\/j.lungcan.2020.02.005_bib0115","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"June 6","key":"10.1016\/j.lungcan.2020.02.005_bib0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"year":"2019","series-title":"Trabectedin: Activity and Safety in Pretreated Epithelioid or biphasic\/sarcomatoid Malignant Pleural Mesothelioma (MPM). IASLC 2019 Mesothelioma Meeting. 10\u201312 July","author":"Cortinovis","key":"10.1016\/j.lungcan.2020.02.005_bib0125"},{"year":"2019","series-title":"SAKK 17\/16 Lurbinectedin As Second or Third Line Palliative Chemotherapy in Malignant Pleural Mesothelioma (mpm): a Multi Center, Single Arm Phase II Trial","author":"Metaxas","key":"10.1016\/j.lungcan.2020.02.005_bib0130"},{"issue":"February 2","key":"10.1016\/j.lungcan.2020.02.005_bib0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"March 3","key":"10.1016\/j.lungcan.2020.02.005_bib0140","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"year":"2019","series-title":". A Multicentre Randomized Phase III Trial Comparing Pembrolizumab (P) Vs Single Agent Chemotherapy (CT) for Advanced Pre Treated Malignant Pleural Mesothelioma (MPM) Results From the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso Trial","author":"Popat","key":"10.1016\/j.lungcan.2020.02.005_bib0145"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:04Z","timestamp":1759236244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":29,"alternative-id":["S0169500220303019"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}